Sichuan Provincial People's Hospital
四川省人民医院
Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Sichuan Provincial People's Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌3 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌5 papers led
- Hepatocellular carcinoma肝细胞癌42 papers led
- Stomach cancer胃癌24 papers led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤6 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
- Neuroblastoma神经母细胞瘤2 papers led
- Multiple myeloma多发性骨髓瘤13 papers led
- Haemophilia A血友病 A0 papers led
- Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病7 papers led
- Myasthenia gravis重症肌无力2 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
- Takayasu arteritis大动脉炎0 papers led
- Hepatic echinococcosis肝包虫病10 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化17 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
- Behçet disease白塞病1 paper led
- Alport syndromeAlport 综合征1 paper led
- IgA nephropathyIgA 肾病10 papers led1 open trial led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
- Congenital diaphragmatic hernia先天性膈疝1 paper led
- Hereditary angioedema遗传性血管性水肿1 paper led
- Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led
Not listed for: Hepatoblastoma, Retinoblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Hirschsprung disease, Inherited epidermolysis bullosa, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- Quantitative parameter analysis of pretreatment dual-energy computed tomography in nasopharyngeal carcinoma cervical lymph node characteristics and prediction of radiotherapy sensitivity.
- Nomogram to Predict Long-Term Overall Survival and Cancer-Specific Survival of Radiotherapy Patients with Nasopharyngeal Carcinoma.
- YAP nuclear translocation facilitates radiation resistance in nasopharyngeal carcinoma cells.
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)11
- Additional file 1 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 2 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 3 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 4 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 5 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 6 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 7 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
- Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma
- 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
- High-Dose Intravenous Acyclovir Is Safe and Effective in the Treatment of EBV Reactivation Post Allogeneic Hematopoietic Stem Cell Transplantation
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 5 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Chengdu for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- RSK Inhibition Rewires Kinase Networks and Triggers Cascading Pathway Disruption in Esophageal Cancer.
- LncRNA HOXA11-AS promotes the cell proliferation, migration, invasion and inhibits cell apoptosis in esophageal squamous cell carcinoma.
- Tumor-Resident Microbiota-Based Risk Model Predicts Neoadjuvant Therapy Response of Locally Advanced Esophageal Squamous Cell Carcinoma Patients.
- Esophageal mixed or collision small cell-squamous cell carcinoma: Report of 6 cases and review of the literature.
- Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma.
All its trials on ClinicalTrials.gov, any status5
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)7
- Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
- 1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- KRT17 Facilitates Proliferation, Migration and Invasion in Esophageal Squamous Cell Carcinoma by Regulating mTOR/S6K1 pathway
Cancer
Hepatocellular carcinoma
肝细胞癌Led 42 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led42
- ATG9A-PLA2G6 axis reprograms phospholipid metabolism to drive metabolic liver disease and hepatocellular carcinoma.
- Unveiling EMC6 as a novel pathogenic determinant in hepatocellular carcinoma: orchestration of lipid metabolism through regulation of lipid droplet-associated enzyme HSD17B13.
- ZDHHC12 Palmitoylates HDAC8 to Promote the Progression of Hepatocellular Carcinoma Associated with a Diet High in Saturated Fatty Acids.
- Nanomedicine-unlocked radiofrequency dynamic therapy dampens incomplete radiofrequency ablation-arised immunosuppression to suppress cancer relapse.
- Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
- The impact of metabolic reprogramming in hepatocellular carcinoma on T cell.
- Dysregulated arginine metabolism is associated with pro-tumor neutrophil polarization in liver cancer.
- Clinical potential and experimental validation of prognostic genes in hepatocellular carcinoma revealed by risk modeling utilizing single cell and transcriptome constructs.
- Reprogramming cysteine metabolism via METTL14-SLC7A11 axis promotes the progression of NAFLD and hepatocellular carcinoma.
- Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization.
- Radiomics features based on dual-area CT predict the expression levels of fatty acid binding protein 4 and outcome in hepatocellular carcinoma.
- Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials.
- Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression.
- -RAMP3 promotes hepatocellular carcinoma tumor cell-mediated CCL2 degradation by supporting membrane distribution of ACKR2.
- Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
- Integrated clinical and prognostic analyses of mTOR/Hippo pathway core genes in hepatocellular carcinoma.
- Quercetin inhibits endothelial & hepatocellular carcinoma cell crosstalk via reducing extracellular vesicle-mediated VEGFR2 mRNA transfer.
- USP26 as a hepatitis B virus-induced deubiquitinase primes hepatocellular carcinogenesis by epigenetic remodeling.
- Excessive SOX8 reprograms energy and iron metabolism to prime hepatocellular carcinoma for ferroptosis.
- HMMR triggers immune evasion of hepatocellular carcinoma by inactivation of phagocyte killing.
- NOP16 promotes hepatocellular carcinoma progression and triggers EMT through the Keap1-Nrf2 signaling pathway.
- Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.
- Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis.
- Gene variation profile and it's potential correlation with clinical characteristics in HBV-associated HCC patients of Sichuan Han nationality in China.
- Fluorescence-guided single-incision laparoscopic left hemihepatectomy for hepatocellular carcinoma: A case report.
- ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma.
- TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs.
- Comment on: A nomogram for predicting acute kidney injury following hepatectomy: A propensity score matching analysis.
- Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.
- ST8SIA6-AS1 contributes to hepatocellular carcinoma progression by targeting miR-142-3p/HMGA1 axis.
- Comparative study of indocyanine green (ICG)-R15 and Albumin-Indocyanine Green Evaluation (ALICE) grading system in the prediction of posthepatectomy liver failure and postoperative mortality in patients with hepatic alveolar echinococcosis
- Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR-147a/ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma.
- Monosegmental ALPPS combined with ante-situm liver resection: A novel strategy for end-stage hepatic alveolar echinococcosis.
- Prognostic value of inflammation-immunity-nutrition score in patients with hepatocellular carcinoma treated with anti-PD-1 therapy.
- Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma.
- Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma.
- A systematic review and meta-analysis on prognosis and survival of hepatocellular carcinoma with lung metastasis after hepatectomy.
- RABL2A-CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma.
- DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
- Ras Homolog Family Member F, Filopodia Associated Promotes Hepatocellular Carcinoma Metastasis by Altering the Metabolic Status of Cancer Cells Through RAB3D.
- LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway.
- LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1.
All its trials on ClinicalTrials.gov, any status1
Cancer
Stomach cancer
胃癌Led 24 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
5 hospitals in Chengdu for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led24
- Impacts of omega-3 fatty acids intervention on immune functions and clinical outcomes in surgical gastric cancer patients: a systematic review and trial sequential meta-analysis.
- Dual-phase contrast-enhanced CT-based intratumoral and peritumoral radiomics for preoperative prediction of lymph node metastasis in gastric cancer.
- Dual-phase contrast-enhanced CT-based intratumoral and peritumoral radiomics for preoperative prediction of lymphovascular invasion in gastric cancer.
- Prenatal and Postnatal Ultrasonographic Characteristics of Immature Teratoma in the Gastric Wall: A Case Report.
- IGF2BP3 boosts lactate generation to accelerate gastric cancer immune evasion.
- A novel entire traction method using a clip-anchored nylon ring to facilitate endoscopic submucosal dissection for gastric submucosal protrusion lesions.
- FAM120A deficiency improves resistance to cisplatin in gastric cancer by promoting ferroptosis.
- Dental floss with rubber band-formed pulley traction facilitating endoscopic full-thickness resection of gastric submucosal tumor in gastric fundus.
- Initial validation of the clinical significance of the NETest in Japanese gastroenteropancreatic neuroendocrine tumor patients.
- Internal and external bidirectional traction facilitating endoscopic submucosal excavation of a huge subepithelial tumor in the fornix of the gastric fundus near the cardia.
- Snare-based preliminary traction method facilitating endoscopic full-thickness resection of a bidirectional prominent dumbbell-shaped GI stromal tumor in gastric fundus (with video).
- A novel entire traction method with clip-anchored nylon ring facilitating endoscopic submucosal dissection of early gastric cancer.
- Construction of molecular subtype and prognostic model for gastric cancer based on nucleus-encoded mitochondrial genes.
- Clinical application of oral contrast-enhanced ultrasound in evaluating the preoperative T staging of gastric cancer.
- Senescence-related genes define prognosis, immune contexture, and pharmacological response in gastric cancer.
- Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways.
- Proactive over reactive: the snare-based pretraction method improving the full-thickness resection of a large gastrointestinal stromal tumor.
- A novel countertraction-assisted technique facilitating endoscopic submucosal dissection of early gastric angle cancer without the use of a transparent hood.
- Inner countertraction facilitating endoscopic submucosal dissection of a difficult early gastric cancer independent of transparent cap.
- Endoscopic closure of a large gastric mucosal defect after endoscopic submucosal dissection using a novel endoscopic string-with-knotter suture device.
- NAE modulators: A potential therapy for gastric carcinoma.
- N6-methyladenosine (m6A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner.
- Cut the weeds and dig up the roots: clip-and-snare assisted endoscopic mucosal resection of a rectal neuroendocrine tumor.
- Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status6
- Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chengdu for chordoma84 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Chengdu for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- Single Cell Geometry Regulates Self-Renewal Factors in Osteosarcoma Cells via WDR5 Dependent Chromatin Methylation.
- pH-responsive hydrogel with gambogic acid and calcium nanowires for promoting mitochondrial apoptosis in osteosarcoma.
- Mechanism by which CAP regulates the "cold-heat" balance in osteosarcoma model mice: an integrative study of metabolomics, transcriptomics, and network pharmacology.
- FOSL1 promotes stem cell‑like characteristics and anoikis resistance to facilitate tumorigenesis and metastasis in osteosarcoma by targeting SOX2.
- Capsaicin Enhanced the Efficacy of Photodynamic Therapy Against Osteosarcoma via a Pro-Death Strategy by Inducing Ferroptosis and Alleviating Hypoxia.
- Primary osteosarcoma of the thoracic vertebrae: A case report and literature review.
Earlier papers (2016–2020)3
- [Comparison of radiological and clinicopathological features of craniofacial fibro-osseous lesions].
- [Effect of attenuated expression of neuraminidase 3 via RNA interference on the proliferation and apoptosis of osteosarcoma MG-63 cells].
- Identification of characteristic gene modules of osteosarcoma using bioinformatics analysis indicates the possible molecular pathogenesis.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Snare-based preliminary traction method facilitating endoscopic full-thickness resection of a bidirectional prominent dumbbell-shaped GI stromal tumor in gastric fundus (with video).
- Metanephric stromal tumor in an adult with PDGFRA mutation: a case report.
- Proactive over reactive: the snare-based pretraction method improving the full-thickness resection of a large gastrointestinal stromal tumor.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Chengdu for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 13 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Chengdu for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07258511
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingIsatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07663253
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led13
- Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?
- Prognostic value of fatty acid metabolism-related signature and integrated analysis of the immune microenvironment in multiple myeloma.
- Integrating single-cell and bulk RNA profiles to uncover glutamine metabolism's role in prognosis and immune dynamics in multiple myeloma.
- The impact of STAiR18 on multiple myeloma survival rates.
- Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma.
- METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m6A-dependent manner.
- Identification of mutation gene prognostic biomarker in multiple myeloma through gene panel exome sequencing and transcriptome analysis in Chinese population.
- Advances in research on potential inhibitors of multiple myeloma.
- A review on the treatment of multiple myeloma with small molecular agents in the past five years.
- Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications.
- Exploring the R-ISS stage-specific regular networks in the progression of multiple myeloma at single-cell resolution.
- Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM).
- Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Chinese-language papers (not in the count)4
- [Retrospective clinical study on cryopreservation-free integrated autologous hematopoietic stem cell transplantation model for newly diagnosed multiple myeloma].
- [Correlation between Serum Free Light Chain and Blood Routine Parameters in Patients with Multiple Myeloma].
- [Clinical Role of M Protein in Multiple Myeloma and Lymphoma --Review].
- [Research Progress of Intercellular Mitochondrial Transfer in the Development of Hematological Malignant Tumors --Review].
All its trials on ClinicalTrials.gov, any status11
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Blood disorders
Haemophilia A
血友病 ALed no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Chengdu for haemophilia A132 hospitals in China for haemophilia A
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEvaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06111638
Age 18 years to Not stated; men only (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Atypical haemolytic uraemic syndrome
非典型溶血性尿毒症综合征Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Chengdu for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome
No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 7 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Chengdu for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- GD3 antibody subtyping reveals central-peripheral dichotomy in autoimmune neurological disorders.
- Apathy in patients with Neuromyelitis Optica Spectrum Disorder.
- Exploring resting-state EEG oscillations in patients with Neuromyelitis Optica Spectrum Disorder.
- Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients.
- The nutritional risk in patients with neuromyelitis optica spectrum disorder.
- The pathogenesis and treatment of posterior reversible encephalopathy syndrome after neuromyelitis optica spectrum disorder: a case report and literature review.
- The role of basal ganglia network in neural plasticity in neuromyelitis optica spectrum disorder with myelitis.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)1
Other diseases
Myasthenia gravis
重症肌无力Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Chengdu for myasthenia gravis89 hospitals in China for myasthenia gravis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07215650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou
- RecruitingA Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06447597
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
- Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database.
- A case of immune-related adverse events, thyroid dysfunction, myocarditis with myositis, and myasthenia gravis overlap syndrome following serplulimab administration for lung adenocarcinoma.
All its trials on ClinicalTrials.gov, any status5
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Chengdu for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Hepatic echinococcosis
肝包虫病Led 10 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 6.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led10
- A liver CT based nomogram to preoperatively predict lung metastasis secondary to hepatic alveolar echinococcosis.
- CT imaging features and diagnostic algorithm for hepatic cystic echinococcosis.
- Liver vein deprivation combined with two-step hepatectomy for the treatment of advanced hepatic alveolar echinococcosis with remnant liver volume deficiency.
- Liver resection with two-step vascular exclusion, in situ hypothermic portal perfusion for the treatment of end-stage hepatic alveolar echinococcosis.
- Goal-directed fluid therapy for a patient undergoing liver resection for giant hepatic alveolar echinococcosis based on hypotension prediction index.
- Hepatic caudate epithelioid angiomyolipoma mimicking hydatid cyst.
- Comparative study of indocyanine green (ICG)-R15 and Albumin-Indocyanine Green Evaluation (ALICE) grading system in the prediction of posthepatectomy liver failure and postoperative mortality in patients with hepatic alveolar echinococcosis
- Monosegmental ALPPS combined with ante-situm liver resection: A novel strategy for end-stage hepatic alveolar echinococcosis.
- Comment on "The Value of Hepatic Vein Stent Placement as a Bridge Therapy on Treating Hepatic Alveolar Echinococcosis Presenting With Budd-Chiari Syndrome".
- The Value of Hepatic Vein Stent Placement as a Bridge Therapy on Treating Hepatic Alveolar Echinococcosis Presenting With Budd-Chiari Syndrome.
Earlier papers (2016–2020)7
- Current status of ex-vivo liver resection and autologous liver transplantation for end-stage hepatic alveolar echinococcosis.
- Hepatobiliary and Pancreatic: Hepatic cystadenoma mimics hepatic cystic echinococcsis.
- Tibetan patients with hepatic hydatidosis can tolerate hypoxic environment without incident increase of pulmonary hypertension: an echocardiography study.
- Effect of the transversus abdominis plane block on postoperative pain and recovery in patients with hepatic echinococcosis.
- Preliminary experience in laparoscopic resection of hepatic hydatidectocyst with the Da Vinci Surgical System (DVSS): a case report.
- Enhanced recovery after surgery program in patients from Tibet Plateau undergoing surgeries for hepatic alveolar echinococcosis.
- Analysis of contrast-enhanced ultrasound (CEUS) and pathological images of hepatic alveolar echinococcosis (HAE) lesions.
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 17 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
13 hospitals in Chengdu for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07121413
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led17
- Ferroptosis in idiopathic pulmonary fibrosis: mechanisms, impact, and therapeutic opportunities.
- Identification of diagnostic and prognostic phospholipid biomarkers in idiopathic pulmonary fibrosis via machine learning and in vivo validation.
- Exploring ABHD5 as a Lipid-Related Biomarker in Idiopathic Pulmonary Fibrosis: Integrating Machine Learning, Bioinformatics, and In Vitro Experiments.
- Higher mitochondrial protein-Succinylation detected in lung tissues of idiopathic pulmonary fibrosis patients.
- Machine learning identifies lipid-associated genes and constructs diagnostic and prognostic models for idiopathic pulmonary fibrosis.
- Integrating cellular experiments, single-cell sequencing, and machine learning to identify endoplasmic reticulum stress biomarkers in idiopathic pulmonary fibrosis.
- Anxiety and depression status in patients with idiopathic pulmonary fibrosis and outcomes of nintedanib treatment: an observational study.
- Body mass index and weight loss as risk factors for poor outcomes in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
- Comprehensive review of potential drugs with anti-pulmonary fibrosis properties.
- Anoikis and SPP1 in idiopathic pulmonary fibrosis: integrating bioinformatics, cell, and animal studies to explore prognostic biomarkers and PI3K/AKT signaling regulation.
- Involvement of E3 ubiquitin ligase NEDD4-mediated YY1 ubiquitination in alleviating idiopathic pulmonary fibrosis.
- FSTL1 promotes alveolar epithelial cell aging and worsens pulmonary fibrosis by affecting SENP1-mediated DeSUMOylation.
- The molecular mechanism underlying dermatomyositis related interstitial lung disease: evidence from bioinformatic analysis and in vivo validation.
- Potential targeted therapy based on deep insight into the relationship between the pulmonary microbiota and immune regulation in lung fibrosis.
- Roles of lipid metabolism and its regulatory mechanism in idiopathic pulmonary fibrosis: A review.
- SENP1 regulates the transformation of lung resident mesenchymal stem cells and is associated with idiopathic pulmonary fibrosis progression.
- Exosomes derived from hypoxia-induced alveolar epithelial cells stimulate interstitial pulmonary fibrosis through a HOTAIRM1-dependent mechanism.
Earlier papers (2016–2020)4
- Transcription factor YY1 inhibits the expression of THY1 to promote interstitial pulmonary fibrosis by activating the HSF1/miR-214 axis.
- Clinical Research on Prognostic Evaluation of Subjects With IPF by Peripheral Blood Biomarkers, Quantitative Imaging Characteristics and Pulmonary Function Parameters.
- In Silico Detection and Characterization of microRNAs and Their Target Genes in microRNA Microarray Datasets from Patients with Systemic Sclerosis-Interstitial Lung Disease.
- Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
All its trials on ClinicalTrials.gov, any status6
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Chengdu for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led5
- Nerve Conduction Study and the Prognosis of Amyotrophic Lateral Sclerosis: Exploration of Additional Neuroelectrophysiological Parameters.
- Rapid eye movement sleep behavior disorder (RBD) and neurodegenerative diseases: A bidirectional 2-sample Mendelian randomization study.
- Atopic dermatitis in amyotrophic lateral sclerosis successfully treated by dupilumab: A case report.
- Integrative analysis of metabolomics and proteomics unravels purine metabolism dysregulation in the SOD1G93A mouse model of amyotrophic lateral sclerosis.
- A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Alport syndrome
Alport 综合征Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chengdu for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 10 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.4%.
8 hospitals in Chengdu for IgA nephropathy300 hospitals in China for IgA nephropathy
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT06676007
Age 18 years to 75 years (registered criteria)
Led by Sichuan Provincial People's HospitalChengdu
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led10
- Non-Invasive Early Detection of Tubular Atrophy and Interstitial Fibrosis in Immunoglobulin A Nephropathy Using [18F] AlF-NOTA-FAPI-04 PET/CT: A Pilot Study.
- Clinicopathological characteristics and predictors of renal outcomes in diffuse crescentic glomerulonephritis : a retrospective single-center study from Western China.
- Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review.
- Research Progress of Pyroptosis in Renal Diseases.
- The effects of apoptosis inhibitor of macrophage in kidney diseases.
- Long-term renal survival in patients with IgA nephropathy: a systematic review.
- Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics.
- HLA-DQB1 and HLA-DRB1 expression is associated with disease severity in IgAN.
- Levels of Apelin-12, AT1R, and AGT are correlated with degree of renal fibrosis in patients with immunoglobulin A nephropathy.
- The prognostic value of platelet-to-lymphocyte ratio on the long-term renal survival in patients with IgA nephropathy.
Earlier papers (2016–2020)3
- Association of high body mass index with development of interstitial fibrosis in patients with IgA nephropathy.
- A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study.
- Replication of genome-wide association study identified seven susceptibility genes, affirming the effect of rs2856717 on renal function and poor outcome of IgA nephropathy.
All its trials on ClinicalTrials.gov, any status9
- A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- Relative Bioavailability Study of HR19042 in Healthy Subjects
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Chengdu for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingFenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Phase
- Phase 2/Phase 3
- Started
- 2023-02
- Registry
- NCT05749822
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Chengdu for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Hereditary angioedema
遗传性血管性水肿Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other linked evidence
Getting in touch
Name card to show staff or a driver
四川省人民医院
Sichuan Provincial People's Hospital
成都
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Sichuan Academy of Medical Sciences; Sichuan Provincial Peoples Hospital; Sichuan People's Hospital of Sichuan Academy of Medical Sciences; Sichuan Provincial People's Hospital·Qionglai Medical Center Hospital; Dongli Medical District of Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital Jinniu Hospital; Sichuan Provincial People's Hospital Qionglai Medical Center Hospital; Sichuan Provincial People's Hospital Affiliate Wenjiang Hospital